Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ACK
|
|||
| Drug Name |
Anti-CD30 CAR T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1/2 | [1] | |
| Company |
Peking University
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphocyte activation antigen CD30 (TNFRSF8) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.